Patents by Inventor Jan Markussen

Jan Markussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9260501
    Abstract: Insulins to which there is connected an amino acid oligomer have satisfactory properties.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 16, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Høeg-Jensen, Thomas Børglum Kjeldsen, Jan Markussen
  • Patent number: 8835132
    Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: September 16, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Ib Jonassen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
  • Publication number: 20100069605
    Abstract: Insulins to which there is connected an amino acid oligomer have satisfactory properties.
    Type: Application
    Filed: October 29, 2007
    Publication date: March 18, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Thomas Høeg-Jensen, Thomas Børglum Kjeldsen, Jan Markussen
  • Publication number: 20100055738
    Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.
    Type: Application
    Filed: August 18, 2009
    Publication date: March 4, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Ib Jonassen, Michi Egel- Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
  • Patent number: 7595172
    Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: September 29, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Ib Jonassen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers, Thomas Borglum Kjeldsen
  • Patent number: 7572884
    Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: August 11, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Hoeg-Jensen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers
  • Patent number: 7402565
    Abstract: A method is provided which allows high yields of acylated insulin. The method comprises expressing a singe-chain insulin precursor, preferably in yeast, cleaving the single-chain insulin precursor with a suitable protease which will open the peptide bond between the C-terminal amino group in the B-chain and a connecting peptide connecting the B chain with the A-chain, acylating the two-chain insulin intermediate in the ?-amino group in LysB29 and subjecting the acylated two-chain insulin intermediate to a proteolytic enzyme which will cleave of the N-terminal extension on the B- and A-chains on the precursor molecule.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: July 22, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Børglum Kjeldsen, Jan Markussen
  • Patent number: 7317000
    Abstract: The present invention relates to insulin derivatives having a built-in glucose sensor and a polyol moiety, capable to deliver insulin from an injected depot of an insulin derivative according to the invention as a function of the glucose concentration in the surrounding tissue.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: January 8, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Hoeg-Jensen, Svend Havelund, Jan Markussen
  • Patent number: 7316999
    Abstract: Insulin derivatives having a built-in glucose sensor, capable of delivering insulin from a depot as a function of the glucose concentration in the surrounding medium (e.g. tissue), such that the rate of insulin release from the depot increases with an increased glucose concentration and decreases with a decreased glucose concentration.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: January 8, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Hoeg-Jensen, Svend Havelund, Jan Markussen, Soren Ostergaard, Signe Ridderberg, Per Balschmidt, Lauge Schaffer, Ib Jonassen
  • Patent number: 7229964
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the ?-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: June 12, 2007
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Publication number: 20060264606
    Abstract: A method is provided which allows high yields of acylated insulin. The method comprises expressing a singe-chain insulin precursor, preferably in yeast, cleaving the single-chain insulin precursor with a suitable protease which will open the peptide bond between the C-terminal amino group in the B-chain and a connecting peptide connecting the B chain with the A-chain, acylating the two-chain insulin intermediate in the ?-amino group in LysB29 and subjecting the acylated two-chain insulin intermediate to a proteolytic enzyme which will cleave of the N-terminal extension on the B- and A-chains on the precursor molecule.
    Type: Application
    Filed: May 3, 2006
    Publication date: November 23, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Thomas Kjeldsen, Jan Markussen
  • Publication number: 20060030518
    Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the C-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.
    Type: Application
    Filed: June 28, 2005
    Publication date: February 9, 2006
    Inventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Andersen, Jan Markussen
  • Publication number: 20060003421
    Abstract: Process for purifying a fermentation-derived product.
    Type: Application
    Filed: September 6, 2005
    Publication date: January 5, 2006
    Applicant: Novo Nordisk A/S
    Inventors: Jan Markussen, Ivan Diers
  • Publication number: 20050272125
    Abstract: The present invention related to a method of producing polypeptides in transformed host cells by expressing a precursor molecule of the desired polypeptide which are to be acylated in a subsequent in vitro step. The invention is also related to DNA-sequences, vectors and transformed host cells for use in the claimed method. Further, the present invention is related to certain precursors of the desired polypeptides and certain acylation methods. The invention provides a method for making polypeptides being preferentially acylated in certain lysine ?-amino groups.
    Type: Application
    Filed: July 28, 2005
    Publication date: December 8, 2005
    Inventors: Thomas Hoeg-Jensen, Michi Egel-Mitani, Per Balschmidt, Jan Markussen, Ivan Diers
  • Patent number: 6869930
    Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ?-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.
    Type: Grant
    Filed: September 17, 1999
    Date of Patent: March 22, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
  • Publication number: 20040137571
    Abstract: Process for purifying a fermentation-derived product.
    Type: Application
    Filed: November 21, 2003
    Publication date: July 15, 2004
    Inventors: Jan Markussen, Ivan Diers
  • Publication number: 20040110664
    Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the &egr;-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the &egr;-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.
    Type: Application
    Filed: March 12, 2002
    Publication date: June 10, 2004
    Inventors: Svend Havelund, John Halstrom, Ib Jonassen, Asser Sloth Andersen, Jan Markussen
  • Publication number: 20040067874
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Application
    Filed: July 16, 2003
    Publication date: April 8, 2004
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Publication number: 20030186846
    Abstract: The present invention relates to insulin derivatives having a built-in glucose sensor and a polyol moiety, capable to deliver insulin from an injected depot of an insulin derivative according to the invention as a function of the glucose concentration in the surrounding tissue.
    Type: Application
    Filed: December 2, 2002
    Publication date: October 2, 2003
    Inventors: Thomas Hoeg-Jensen, Svend Havelund, Jan Markussen
  • Patent number: 6620780
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: September 16, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm